Business
Hemostemix Announces Dr. Mary Argent-Katwala as Its Clinical Trial Manager
Calgary, Alberta--(Newsfile Corp. - June 3, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMT...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Announces Dr. Mary Argent-Katwala as Its Clinical Trial ManagerCalgary, Alberta--(Newsfile Corp. - June 3, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (\"Hemostemix\" or the \"Company\") is pleased to announce the appointment of Dr. Mary Argent-Katwala to the position of Manager, Clinical Trials.Dr. Argent-Katwala earned her PhD in molecular biology from the Institute of Cancer Research, University of London, UK and her MA (Hons.), Biological Sciences at Newnham College, University of Cambridge, UK. Previously, Dr. Argent-Katwala was Director, Diagnosis & Clinical Care at the Canadian Partnership Against Cancer, Toronto, ON where she created a portfolio of high-impact investments to address key issues in the diagnosis and treatment of cancer. Prior to joining the Partnership, Dr. Argent-Katwala held progressive positions with the Decision Resources Group in both Toronto, ON and London, UK, with her most recent assignment being Vice President, Therapy, Reports & Consulting. Dr. Argent-Katwala directed teams analyzing market dynamics, patterns of care and emerging therapies across all therapeutic areas in the G7 and BRIC regions for clients in the pharma, biotech and medical device industries. \"Dr. Argent-Katwala is a great addition to our team,\" said Thomas Smeenk, President & CEO. \"She has a complete understanding of the science of ACP-01, the track record of generating meaningful analyses of each of our markets to help us focus trials in our key revenue streams, and combines that with the relationship-based experience from which to inspire confidence in our partnerships and our clinical trial programs,\" Smeenk said. \"I'm delighted to join Hemostemix at this exciting time for the company and I look forward to advancing the development of ACP-01 and bringing hope to patients and their families,\" said Dr. Argent-Katwala.ABOUT HEMOSTEMIXHemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its saf...